For CROs running trials around the globe, amassing loads of data is no sweat, but sharing it with sponsors in disparate countries and keeping it all in line for an eventual regulatory application can be daunting. With that in mind, WuXi PharmaTech ($WX), Inflamax Research and CROS NT have all signed deals for eClinical software to manage their trials.
WuXi has signed on with Pennsylvania's Instem, giving the Chinese CRO giant a remote study monitoring software called Provantis Portal. The platform allows WuXi's toxicology clients to log on to secure server and view study data from anywhere in the world, enabling sponsors and investigators to monitor results and communication with one another throughout the process.
CRO Inflamax struck up a deal with Florida's OmniComm Systems, signing a 5-year agreement to use the company's eClinical Suite, an end-to-end trial planning and management platform. With OmniComm's software, Inflamax can plot each stage of a study and then capture, manage, clean, export and lock results through an electronic data capture system.
Finally, growing outsourcer CROS NT has joined with eClinical heavyweight Datatrak ($DTRK), enrolling in the Datatrak Connect partner program that gives it access to a full suite of software solutions for drug development.
The rapid growth of multinational CROs has created a serious demand for data management solutions and platforms that allow for cloud-based collaboration. Last month, at the Drug Information Association conference in Boston, a trip down any aisle revealed booth after booth of startups touting their algorithms, software and optimization systems as just what investigators need to wrangle unwieldy data. And, considering how frequently CROs are striking deals with eClinical providers, they seem to be making their point.
- read the Instem announcement
- here's OmniComm's statement
- check out Datatrak's release